Hinge Health (NYSE:HNGE) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Hinge Health (NYSE:HNGE) had its target price lifted by investment analysts at Stifel Nicolaus from $130.00 to $135.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus‘s price target indicates a potential upside of 17.27% from the stock’s previous close.

A number of other brokerages also recently issued reports on HNGE. Royal Bank Of Canada upped their price objective on shares of Hinge Health from $75.00 to $110.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Morgan Stanley increased their price objective on shares of Hinge Health from $72.00 to $108.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Citigroup reissued an “outperform” rating on shares of Hinge Health in a research report on Monday, July 27th. KeyCorp boosted their target price on Hinge Health from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Friday, October 16th. Finally, Weiss Ratings lowered Hinge Health from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $111.60.

Hinge Health Price Performance

NYSE HNGE opened at $115.11 on Tuesday. Hinge Health has a 1 year low of $30.08 and a 1 year high of $118.87. The firm has a market cap of $9.29 billion, a price-to-earnings ratio of 89.36 and a beta of 1.37. The company has a fifty day moving average price of $98.66 and a 200-day moving average price of $67.35.

Hinge Health (NYSE:HNGE) last announced its earnings results on Monday, November 2nd. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.27 by $0.44. Hinge Health had a net margin of 15.15% and a return on equity of 51.60%. The company had revenue of $234.97 million during the quarter. During the same quarter in the prior year, the company earned ($0.02) EPS. The business’s revenue for the quarter was up 52.4% on a year-over-year basis. On average, research analysts anticipate that Hinge Health will post 1.25 EPS for the current fiscal year.

Insider Activity at Hinge Health

In other news, President James Pursley sold 33,000 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $88.05, for a total transaction of $2,905,650.00. Following the completion of the sale, the president owned 706,235 shares in the company, valued at $62,183,991.75. This trade represents a 4.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Perez sold 150,000 shares of Hinge Health stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $89.44, for a total transaction of $13,416,000.00. Following the completion of the sale, the chief executive officer directly owned 35,470 shares in the company, valued at $3,172,436.80. This trade represents a 80.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,024,581 shares of company stock valued at $95,632,761 in the last three months. Insiders own 18.92% of the company’s stock.

Hedge Funds Weigh In On Hinge Health

Several institutional investors and hedge funds have recently bought and sold shares of the company. SBI Securities Co. Ltd. increased its position in Hinge Health by 39.5% in the third quarter. SBI Securities Co. Ltd. now owns 364 shares of the company’s stock worth $35,000 after buying an additional 103 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Hinge Health by 2.1% in the third quarter. ProShare Advisors LLC now owns 5,588 shares of the company’s stock valued at $543,000 after buying an additional 117 shares during the period. IFP Advisors Inc lifted its position in shares of Hinge Health by 140.0% during the 2nd quarter. IFP Advisors Inc now owns 324 shares of the company’s stock valued at $27,000 after buying an additional 189 shares during the last quarter. Janney Montgomery Scott LLC lifted its position in shares of Hinge Health by 3.3% during the 1st quarter. Janney Montgomery Scott LLC now owns 9,400 shares of the company’s stock valued at $362,000 after buying an additional 300 shares during the last quarter. Finally, Nykredit A S bought a new position in shares of Hinge Health during the 2nd quarter worth $29,000.

Hinge Health News Roundup

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Quarterly results exceeded consensus. Hinge Health generated approximately $235.0 million in revenue, up 52.4% year over year, and reported $0.71 in earnings per share versus estimates ranging from $0.27 to $0.63. The company also posted a 15.15% net margin, reinforcing the improving profitability story. Hinge Health reports record third quarter 2026 financial results
• Positive Sentiment: Management provided a constructive growth outlook. Hinge Health outlined 2026 revenue of $879 million to $881 million, representing another upward outlook adjustment according to coverage of the earnings call. The company also is targeting an integrated gastrointestinal care program for summer 2027, creating a potential new expansion opportunity beyond its core musculoskeletal business. Hinge Health outlines revenue outlook and GI program
• Neutral Sentiment: The earnings reaction was relatively limited. Although Hinge Health cleared published estimates and highlighted record results, reports characterized the stock’s response as muted. With a market capitalization near $9.3 billion, a price-to-earnings ratio around 89, and shares close to their one-year high, much of the strong execution may already be reflected in the valuation. Hinge Health third-quarter results beat forecasts
• Negative Sentiment: Expectations remain a key risk. Some coverage indicated that results missed the higher “whisper” forecast despite beating official consensus estimates. That gap, combined with the stock’s sharp appreciation above its 50-day and 200-day moving averages, could limit further gains unless Hinge Health continues delivering sizable revenue growth and upward guidance revisions. Hinge Health clears consensus but misses the whisper

About Hinge Health

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.